PMV Pharma Q2 2021 net loss $24.5M; cash $339M; PC14586 trial enrollment ongoing

PMV Pharmaceuticals, Inc.

Net loss for H1 2021 was $24.5M vs $15.2M in H1 2020.
Cash, cash equivalents & marketable securities $339.0M at June 30, 2021.
R&D expenses $15.2M (H1 2021) vs $11.8M (H1 2020) on PC14586 development.
Continued enrollment in Phase 1/2 trial of p53 Y220C reactivator PC14586.
Activated 12 clinical trial sites across leading US oncology centers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.